Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Xpeng Inc - ADR (XPEV) Price & Performance

Gilead Sciences, Inc.Trade
Xpeng Inc - ADRTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Xpeng Inc - ADR — how do they compare? Gilead Sciences, Inc. trades at $135.62 (market cap $168.35B), while Xpeng Inc - ADR trades at $11.76 (market cap $11.15B). The key difference: Gilead Sciences, Inc. is far larger — about 15.1× Xpeng Inc - ADR's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.

GILDXPEV
Market Cap
$168.35B$11.15B
Sector
HealthConsumer Cyclical
52-Week High
$155.80$28.07
52-Week Low
$110.56$11.68
Enterprise Value
$191.42B$13.28B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Xpeng Inc - ADR

XPeng (XPEV) trades at $11.76, down 2.04% today, amid a bearish technical signal. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with profitability metrics like ROE at -7.64% remaining weak. Recent news highlights expansion into robotics and overseas markets, including a new SUV launch in Munich, while July 2026 deliveries increased 4% year-over-year to 38,027 vehicles.

The stock offers potential upside to the $17.00 analyst consensus target but faces risks from persistent losses, intense EV competition, and macroeconomic pressures. Investor sentiment is mixed, with 64.7% of analysts rating it a buy, but technical indicators suggest near-term caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Xpeng Inc - ADR

Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

Read more on XPEV